Novartis Ag Stock News

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to

Basel, December 11, 2021 Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix ® (asciminib) demonstrating that the results observed in the primary analysis (24 weeks) vs. Bosulif ® * (bosutinib) were maintained in longer-term follow up for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs) 1-4 .

(RTTNews) - Novartis'' (NVS) Kymriah or tisagenlecleucel demonstrated strong efficacy in high-risk patients with relapsed or refractory follicular lymphoma, as per a subgroup analysis from an about 17-month median follow-up of the pivotal Phase II ELARA study. In the subgroup analysis, results showed high rates of durable responses were induced

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months

Moreno Evelyn V decreased its holdings in shares of Novartis AG (NYSE:NVS) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 91,168 shares of the companys stock after selling 590 shares during the period. Novartis accounts for approximately 1.8% of Moreno Evelyn Vs portfolio, making the stock its 27th biggest position. Moreno Evelyn []

Rosenbaum Jay D. raised its position in Novartis AG (NYSE:NVS) by 3.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,737 shares of the companys stock after acquiring an additional 275 shares during the quarter. Rosenbaum Jay D.s holdings in Novartis were worth $714,000 []

Basel, December 11, 2021 Novartis announced Kymriah ® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase II ELARA study 1 . These results were presented in an oral session at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) (Abstract #131).

Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Na

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/2

Cubic Asset Management LLC boosted its holdings in shares of Novartis AG (NYSE:NVS) by 32.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,040 shares of the companys stock after buying an additional 10,947 shares during the quarter. Cubic Asset Management LLCs holdings []

An active element is an element in a medication drug or pesticide that is biologically active. The similar terms active medication element and bulk active are also used in medicine, and the term active ingredient may be used for natural

DUBLIN--(BUSINESS WIRE)--The "Biosimilar Lymphocyte Modulator Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global biosimilar lymphocyte modulator market is expected to grow from $1.22 billion in 2020 to $1.31 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The market is expected to reach $1.91 billion in 2025 at a CAGR of 10%. Major players in the biosimilar lymphocyte modulator market are Pfizer,

The global Treatment for Hormonal Imbalance market size is projected to reach US$ 27.3 Billion by 2027, at a CAGR of 8.6% during 2021-2027. Hormonal imbalance, including menopause, are the key variables driving the market for chemical substitution treatment. The

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline update…